Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK plus ) advanced solid tumors, including NSCLC: Update from the phase I/II TRIDENT-1 trial

被引:0
作者
Solomon, B. J. [1 ]
Drilon, A. [2 ,3 ]
Lin, J. J. [4 ]
Bazhenova, L. [5 ]
Goto, K. [6 ]
De langen, J. [7 ]
Kim, D-W. [8 ,9 ]
Wolf, J. [10 ]
Springfeld, C. [11 ]
Popat, S. [12 ]
Lim, D. W-T. [13 ]
Baik, C. S. [14 ]
Hervieu, A. [15 ]
Garcia, V. Moreno [16 ]
Yang, N. [17 ]
Thamake, S. [18 ]
Ades, F. [19 ]
Trone, D. [20 ]
Besse, B. [21 ]
机构
[1] Peter MacCallum Canc Ctr, Med Oncol, Melbourne, Vic, Australia
[2] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA
[3] Weill Cornell Med Coll, New York, NY USA
[4] Massachusetts Gen Hosp, Ctr Thorac Cancers, Boston, MA USA
[5] Univ Calif San Diego, Dept Med, Moores Canc Ctr, La Jolla, CA USA
[6] Natl Canc Ctr Hosp East, Thorac Oncol, Kashiwa, Chiba, Japan
[7] Netherlands Canc Inst, Dept Thorac Oncol, Amsterdam, Netherlands
[8] Seoul Natl Univ, Dept Internal Med, Coll Med, Seoul, South Korea
[9] Seoul Natl Univ Hosp, Seoul, South Korea
[10] Univ Hosp Cologne, Dept Internal Med, Ctr Integrated Oncol, Cologne, Germany
[11] NCT Nat Zentrum Tumorerkrankungen, Dept Med Oncol, Heidelberg, Germany
[12] Royal Marsden Hosp NHS Fdn Trust, Dept Med, London, England
[13] Natl Canc Ctr Singapore, Div Med Oncol, Singapore, Singapore
[14] Univ Washington, Thorac Head & Neck Med Oncol, Fred Hutchinson Canc Ctr, Sch Med, Seattle, WA USA
[15] Ctr Georges Francois Leclerc, Med Oncol, Dijon, France
[16] START Madrid FJD, Fdn Jimenez Diaz Hosp, Oncol, Madrid, Spain
[17] Hunan Canc Hosp, Oncol, Changsha, Peoples R China
[18] Turning Point Therapeut Inc, Bristol Myers Squibb Co, Clin Sci, San Diego, CA USA
[19] Bristol Myers Squibb, Clin Sci, Princeton, NJ USA
[20] Bristol Myers Squibb Co, Turning Point Therapeut Inc, Biostat, San Diego, CA USA
[21] Univ Paris Saclay, Gustave Roussy, Villejuif, France
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
1372P
引用
收藏
页数:1
相关论文
empty
未找到相关数据